Further, a CD16/CD19 BiKE and a CD16/CD19/CD22 TriKE have been shown to trigger NK cell activation via CD16 signaling, for which CD16/CD19 TriKE induced better killing of CLL cells in vitro compared to rituximab [90]. This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.